GPC3 and neoplasm: In multivariate analysis adjusted for age, sex, tumor stage (BCLC) and HCC treatment, GPC-3 > 150 pg/mL remained an independent predictor of poorer survival (aHR = 1.68, 95% CI 1.03–2.67, p = 0.036) (Table 2).